AstraZeneca Stock Leads 3 AI Healthcare Picks Worth A Closer Look

Global bond yields have been edging higher as investors react to stubborn inflation signals and shifting expectations for central bank rate paths. That makes dependable growth stories harder to find and increases the appeal of themes linked to real world productivity gains, such as AI in healthcare. This article highlights three stocks from a Transformative AI Healthcare screener that show how this theme plays out in practice.

The three stocks in this article are just a starting sample from the Transformative AI Healthcare idea, and the full screen surfaced 3 more companies with equally compelling narratives that are not covered here. To identify your own highest conviction angles on this theme, head straight to the Transformative Artificial intelligence (AI) Healthcare Stocks screener.

Haleon (LSE:HLN)

Haleon is a global consumer healthcare company behind brands like Sensodyne, Panadol, Advil and Centrum, with a focus on everyday oral health, pain relief, respiratory and vitamin products. It generates about £3.8b from North America, £2.6b from Asia Pacific and £4.7b from Europe, the Middle East, Africa and Latin America, giving it a broad revenue base across regions and categories. The company is valued at roughly £32.2b, which places it among the larger listed consumer health groups.

Investors looking at AI in healthcare may consider Haleon because it combines a large consumer health portfolio with a defined push into data and AI through its alliance with Microsoft, aimed at refining areas such as supply chains and marketing. Earnings growth is described as steady rather than rapid, and the stock is presented as relatively attractive on both P/E and discounted cash flow metrics, while still anchored by recognisable brands that can support pricing power. The trade off is meaningful debt, rising regulatory costs and product recall risks that can affect margins and investor sentiment. For those seeking exposure to AI applied to everyday health products rather than pure software, Haleon represents an alternative angle that may be easy to overlook at first glance.

Haleon’s steady earnings story and push into AI can easily get missed beside flashier software stocks. To see how that mix of brand strength, valuation signals and debt risk fits together, review the 4 key rewards and 1 important warning sign

Build your own AI healthcare shortlist

Haleon and the two other stocks in this article all came from a single Simply Wall St screen, but the real edge is in tailoring the filters to what matters most to you. Use our flexible Screener to mix valuation, growth, quality and risk checks into your own shortlist, or tap into any of our curated Investing Ideas for ready made themes.

IXICO (AIM:IXI)

IXICO is a London based specialist in AI enabled neuroimaging services for biopharma, helping drug developers design and run brain disease trials in areas such as Alzheimer’s, Parkinson’s and Huntington’s. The company generates around £7.3 million from its Medical Labs & Research activities, providing imaging biomarkers, trial management and data analytics on a single platform. With a market value of about £15.8 million, IXICO sits firmly in the micro cap bracket where individual contract wins and clinical partnerships can have a meaningful impact on the story.

IXICO stands out in this AI healthcare theme because it brings deep neuroimaging expertise to some of the toughest diseases, from Alzheimer’s to rare neurological conditions, while still trading around a sales multiple that suggests a discount to larger life sciences peers. Recent contract wins, revenue guidance of at least £8 million for FY2026 and a growing set of collaborations indicate commercial traction; however, the company is still loss making with an earnings outlook that points to further pressure and ongoing funding risk. That mix of growing demand, boardroom reshuffles, share dilution and a volatile share price creates a high risk, high potential setup that may warrant a closer look for investors who are comfortable with small cap swings.

IXICO’s contract momentum and niche in brain disease trials may not be fully reflected in its tiny market value. Get a sharper view of that growth versus funding tension with the 2 key rewards and 4 important warning signs (2 are major!)

AstraZeneca (LSE:AZN)

AstraZeneca is a global biopharmaceutical company that discovers, develops and sells prescription medicines across oncology, cardiovascular and metabolic disease, respiratory and immunology, vaccines and rare diseases. It currently reports all of its roughly $61.4b in annual revenue from pharmaceuticals, reflecting a large and diversified drug portfolio, and has a market value of about £183.7b, putting it in the top tier of global healthcare stocks.

Investors looking at AI in healthcare may pay attention to AstraZeneca because its fast moving oncology and rare disease pipeline, combined with deep AI partnerships in drug discovery and clinical trial design, sits on top of reported fundamentals including 25.9% earnings growth in the past year, a 5 year earnings growth rate of 37.6% a year and a 20.8% ROE. According to Simply Wall St, the stock is framed as trading materially below their fair value estimate, even though the P/E is slightly above the European pharma average, which makes the difference between quality and price worth a closer look. The risks cited include high debt, heavy reliance on blockbuster drugs and recent insider selling, which could amplify any setback in the pipeline or pricing. That mix of reported quality signals, AI exposure and identified risks is presented as the reason why AstraZeneca stands out in this screener.

AstraZeneca’s AI backed drug engine and reported double digit earnings growth could be masking an even bigger story in its valuation. Get the full picture and the trade offs inside the 4 key rewards and 2 important warning signs

Seeking Fresh Alternatives Before Others Do

Fresh stock ideas move from quiet potential to full priced once the crowd catches on. Use these curated screens while they are still under the radar for now and act now.

• Target resilient compounding potential before it gets fully priced by scanning companies in the 7 resilient stocks with low risk scores that still show room for momentum.
• Spot early AI tailwinds in firms already generating cash with the curated 71 profitable AI stocks that aren't just burning cash before sentiment sends valuations higher.
• Position ahead of potential infrastructure build outs with companies in the hand picked 36 power grid technology and infrastructure stocks while interest is still building.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com